Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-244X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan ; volume:14 ; number:1 ; day:7 ; month:4 ; year:2014 ; pages:1-6 ; date:12.2014
BMC psychiatry ; 14, Heft 1 (7.4.2014), 1-6, 12.2014
- Creator
-
Sukegawa, Tsuruhei
- Contributor
-
Inagaki, Ataru
Yamanouchi, Yoshio
Inada, Toshiya
Yoshio, Takashi
Yoshimura, Reiji
Iwata, Nakao
SpringerLink (Online service)
- DOI
-
10.1186/1471-244X-14-103
- URN
-
urn:nbn:de:1111-201607164708
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sukegawa, Tsuruhei
- Inagaki, Ataru
- Yamanouchi, Yoshio
- Inada, Toshiya
- Yoshio, Takashi
- Yoshimura, Reiji
- Iwata, Nakao
- SpringerLink (Online service)
Other Objects (12)
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
Antipsychotic polypharmacy prescribing and risk of hospital readmission
Cost of antipsychotic polypharmacy in the treatment of schizophrenia
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Antipsychotic polypharmacy in a regional health service: a population-based study
Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process
Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
Exploring polypharmacy with artificial intelligence: data analysis protocol
Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
Antipsychotic polypharmacy prescribing and risk of hospital readmission
Cost of antipsychotic polypharmacy in the treatment of schizophrenia
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Antipsychotic polypharmacy in a regional health service: a population-based study
Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process
Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
Exploring polypharmacy with artificial intelligence: data analysis protocol
Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
Antipsychotic polypharmacy prescribing and risk of hospital readmission
Cost of antipsychotic polypharmacy in the treatment of schizophrenia
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Antipsychotic polypharmacy in a regional health service: a population-based study
Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process
Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
Exploring polypharmacy with artificial intelligence: data analysis protocol